0001179110-13-006722.txt : 20130411 0001179110-13-006722.hdr.sgml : 20130411 20130411214502 ACCESSION NUMBER: 0001179110-13-006722 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130410 FILED AS OF DATE: 20130411 DATE AS OF CHANGE: 20130411 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WOOD JULIANNA R CENTRAL INDEX KEY: 0001282660 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28298 FILM NUMBER: 13757364 MAIL ADDRESS: STREET 1: 3031 RESEARCH DR STREET 2: BLDG A CITY: RICHMOND STATE: CA ZIP: 84806 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-0000 MAIL ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgar.xml FORM 4 - X0306 4 2013-04-10 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001282660 WOOD JULIANNA R C/O ONYX PHARMACEUTICALS, INC. 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 VP, Public Affairs Common Stock 2013-04-10 4 M 0 547 35.18 A 19921 D Common Stock 2013-04-10 4 M 0 220 28.55 A 20141 D Common Stock 2013-04-10 4 M 0 1198 37.68 A 21339 D Common Stock 2013-04-10 4 M 0 619 30.28 A 21958 D Common Stock 2013-04-10 4 M 0 600 28.55 A 22558 D Common Stock 2013-04-10 4 M 0 146 30.28 A 22704 D Common Stock 2013-04-10 4 S 0 3330 95.0032 D 19374 D Common Stock 2013-04-10 4 M 0 510 30.28 A 19884 D Common Stock 2013-04-10 4 M 0 440 28.55 A 20324 D Common Stock 2013-04-10 4 M 0 1437 37.68 A 21761 D Common Stock 2013-04-10 4 M 0 3645 35.18 A 25406 D Common Stock 2013-04-10 4 M 0 586 28.55 A 25992 D Common Stock 2013-04-10 4 S 0 6618 95.00 D 19374 D Common Stock 200 I Children's Trust Stock Option (Right to Buy) 35.18 2013-04-10 4 M 0 547 0.00 D 2021-03-31 Common Stock 547 12760 D Stock Option (Right to Buy) 35.18 2013-04-10 4 M 0 3645 0.00 D 2021-03-31 Common Stock 3645 9115 D Stock Option (Right to Buy) 28.55 2013-04-10 4 M 0 220 0.00 D 2019-03-31 Common Stock 220 2173 D Stock Option (Right to Buy) 28.55 2013-04-10 4 M 0 600 0.00 D 2019-03-31 Common Stock 600 1573 D Stock Option (Right to Buy) 28.55 2013-04-10 4 M 0 440 0.00 D 2019-03-31 Common Stock 440 1133 D Stock Option (Right to Buy) 28.55 2013-04-10 4 M 0 586 0.00 D 2019-03-31 Common Stock 586 547 D Stock Option (Right to Buy) 37.68 2013-04-10 4 M 0 1198 0.00 D 2022-03-29 Common Stock 1198 19166 D Stock Option (Right to Buy) 37.68 2013-04-10 4 M 0 1437 0.00 D 2022-03-29 Common Stock 1437 17729 D Stock Option (Right to Buy) 30.28 2013-04-10 4 M 0 619 0.00 D 2020-03-31 Common Stock 619 7291 D Stock Option (Right to Buy) 30.28 2013-04-10 4 M 0 146 0.00 D 2020-03-31 Common Stock 146 7145 D Stock Option (Right to Buy) 30.28 2013-04-10 4 M 0 510 0.00 D 2020-03-31 Common Stock 510 6635 D Shares sold pursuant to a 10b5-1 plan. The shares were sold at prices ranging from $95.00 to $95.08. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months. /s/ Warren DeSouza, Attorney-In-Fact 2013-04-11